Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
Recent data have demonstrated substantial efficacy with poly (ADP-ribose) polymerase (PARP) inhibitors as treatment and/or maintenance therapy in patients with newly diagnosed advanced epithelial ovarian cancer (EOC). Here, we review efficacy and safety results from four recent Phase III trials in n...
Guardado en:
Autores principales: | Paul DiSilvestro, Nicoletta Colombo, Philipp Harter, Antonio González-Martín, Isabelle Ray-Coquard, Robert L. Coleman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7db2bf1fae0248e4b42864c456b631ad |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer
por: Rongjia Su, et al.
Publicado: (2021) -
Prediction of BRCA gene mutation status in epithelial ovarian cancer by radiomics models based on 2D and 3D CT images
por: Liu Mingzhu, et al.
Publicado: (2021) -
Cáncer de mama triple negativo: terapias sistémicas actuales y experiencia local
por: Luque S.,Glomaryeth, et al.
Publicado: (2021) -
BRCA1 and BRCA2mutations in breast cancer patients from Venezuela
por: Lara,Karlena, et al.
Publicado: (2012) -
Analysis of 5382insC (BRCA1) and 6174delT (BRCA2) mutations in 382 healthy Chilean women with a family history of breast cancer
por: JARA,LILIAN, et al.
Publicado: (2002)